Approved for Treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator. Combines ipratropium (anticholinergic) and albuterol (beta-2 agonist) to produce bronchodilation through two complementary mechanisms: blocking muscarinic receptors and stimulating beta-2 adrenergic… Side effects, costs, interactions, manufacturer, and generic alternatives sourced from…
Loading full data from Know Your Drugs Institute…